James Scott McClellan

739 total citations
23 papers, 439 citations indexed

About

James Scott McClellan is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, James Scott McClellan has authored 23 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Oncology and 7 papers in Genetics. Recurrent topics in James Scott McClellan's work include Hematopoietic Stem Cell Transplantation (8 papers), Mesenchymal stem cell research (7 papers) and Acute Myeloid Leukemia Research (4 papers). James Scott McClellan is often cited by papers focused on Hematopoietic Stem Cell Transplantation (8 papers), Mesenchymal stem cell research (7 papers) and Acute Myeloid Leukemia Research (4 papers). James Scott McClellan collaborates with scholars based in United States and India. James Scott McClellan's co-authors include Scott A. Tibbetts, Herbert W. Virgin, Ravindra Majeti, Samuel H. Speck, Shivaprakash Gangappa, Jason Gotlib, Holbrook E. Kohrt, Steven Coutré, Ash A. Alizadeh and Bruno C. Medeiros and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Journal of Virology.

In The Last Decade

James Scott McClellan

22 papers receiving 436 citations

Peers

Countries citing papers authored by James Scott McClellan

Since Specialization

Citations

This map shows the geographic impact of James Scott McClellan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Scott McClellan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Scott McClellan more than expected).

Fields of papers citing papers by James Scott McClellan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Scott McClellan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Scott McClellan. The network helps show where James Scott McClellan may publish in the future.

Co-authorship network of co-authors of James Scott McClellan

This figure shows the co-authorship network connecting the top 25 collaborators of James Scott McClellan. A scholar is included among the top collaborators of James Scott McClellan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Scott McClellan. James Scott McClellan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies 2025 ·Transplantation and Cellular Therapy ·Amandeep Salhotra, Mehrdad Abedi, Samer A. Srour, (unknown), Edmund K. Waller, Hannah Choe, Anna Pavlova, (unknown), James Scott McClellan, Nathaniel B. Fernhoff, Everett Meyer, Robert Lowsky	2
2	Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies 2024 ·Blood ·Mehrdad Abedi, Samer A. Srour, Amandeep Salhotra, (unknown), Edmund K. Waller, Hannah Choe, (unknown), (unknown), James Scott McClellan, Nathaniel B. Fernhoff, Everett Meyer, Robert Lowsky	3
3	A Retrospective Analysis Comparing Orca-T to Post-Transplant Cyclophosphamide Based Allogeneic Hematopoietic Cell Transplant in Patients with Matched Unrelated Donors Receiving Myeloablative Conditioning 2024 ·Transplantation and Cellular Therapy ·(unknown), Caspian Oliai, Sagar S. Patel, Jeremy Pantin, (unknown), Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, (unknown), Irene Agodoa, James Scott McClellan, Nathaniel B. Fernhoff, Mehrdad Abedi, Everett Meyer	0
4	CT-632 Orca-Q Demonstrates Favorable Graft-Versus-Host Disease (GvHD) and Relapse-Free Survival With Haploidentical Donors Without Post-Transplant Cyclophosphamide 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Samer A. Srour, Amandeep Salhotra, Robert Lowsky, (unknown), Ayman Saad, Edmund K. Waller, (unknown), James Scott McClellan, Nathaniel B. Fernhoff, Everett Meyer, Mehrdad Abedi	1
5	High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T 2023 ·Blood ·(unknown), (unknown), Sagar S. Patel, Edmund K. Waller, Jeremy Pantin, Caspian Oliai, James Scott McClellan, Anna Pavlova, Irene Agodoa, Nathaniel B. Fernhoff, Everett Meyer	2
6	Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide 2023 ·Blood ·Samer A. Srour, Amandeep Salhotra, Robert Lowsky, (unknown), Edmund K. Waller, (unknown), James Scott McClellan, Nathaniel B. Fernhoff, Everett Meyer, Mehrdad Abedi	4
7	Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies 2023 ·Blood ·Caspian Oliai, Jeremy Pantin, (unknown), Lori Muffly, Sagar S. Patel, (unknown), Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, James Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett Meyer	2
8	Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T 2022 ·Blood ·Everett Meyer, M. Scott Killian, (unknown), (unknown), Sean Summers, Fernando Teque, James Scott McClellan, Nathaniel B. Fernhoff	1
9	Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide 2022 ·Blood ·Amandeep Salhotra, Samer A. Srour, (unknown), Ayman Saad, Everett Meyer, (unknown), Edmund K. Waller, (unknown), James Scott McClellan, Nathaniel B. Fernhoff, Robert Lowsky, Mehrdad Abedi	4
10	Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages 2015 ·Proceedings of the National Academy of Sciences ·James Scott McClellan, Christopher G. Dove, Andrew J. Gentles, Christine E. Ryan, Ravindra Majeti	44
11	Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin’s lymphoma treated with PEP-C 2012 ·BMJ Case Reports ·Christina To, (unknown), James Scott McClellan, William H. Howard, Nancy J. Fischbein, (unknown), Dean W. Felsher, Alice C. Fan	5
12	Treatment advances have not improved the early death rate in acute promyelocytic leukemia 2011 ·Haematologica ·James Scott McClellan, Holbrook E. Kohrt, Steven Coutré, Jason Gotlib, Ravindra Majeti, Ash A. Alizadeh, Bruno C. Medeiros	101
13	Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. 2009 ·Blood ·Ash A. Alizadeh, James Scott McClellan, Jason Gotlib, Steven Coutré, Ravindra Majeti, Holbrook E. Kohrt, Bruno C. Medeiros	7
14	Effective Control of Chronic γ-Herpesvirus Infection by Unconventional MHC Class Ia–Independent CD8 T Cells 2006 ·PLoS Pathogens ·Douglas Braaten, James Scott McClellan, Ilhem Messaoudi, Scott A. Tibbetts, (unknown), Janko Nikolich‐Žugich, Herbert W. Virgin	21
15	Critical Role of CD4 T Cells in an Antibody-Independent Mechanism of Vaccination against Gammaherpesvirus Latency 2004 ·Journal of Virology ·James Scott McClellan, Scott A. Tibbetts, Shivaprakash Gangappa, (unknown), Herbert W. Virgin	23
16	Effective Vaccination against Long-Term Gammaherpesvirus Latency 2003 ·Journal of Virology ·Scott A. Tibbetts, James Scott McClellan, Shivaprakash Gangappa, Samuel H. Speck, Herbert W. Virgin	58
17	Establishment and Maintenance of Gammaherpesvirus Latency Are Independent of Infective Dose and Route of Infection 2003 ·Journal of Virology ·Scott A. Tibbetts, Joy Loh, Victor van Berkel, James Scott McClellan, Meagan A. Jacoby, Sharookh B. Kapadia, Samuel H. Speck, Herbert W. Virgin	89
18	B-Lymphocyte aggregates in alveoli from a child with hypersensitivity pneumonitis (bird breeders lung) 1999 ·Annals of Allergy Asthma & Immunology ·James Scott McClellan, Gary M. Albers, (unknown), (unknown), (unknown), Alan P. Knutsen	6
19	cDNA cloning, in vitro expression, and biochemical characterization of cholinesterase 1 and cholinesterase 2 from amphioxus 1998 ·European Journal of Biochemistry ·James Scott McClellan, (unknown), (unknown), (unknown), (unknown), (unknown), Caroline Ozment, (unknown), (unknown), (unknown), Elizabeth Palmer, (unknown), Leo Pezzementi	17
20	Two cholinesterase activities and genes are present in amphioxus 1997 ·Journal of Experimental Zoology ·David J. Sutherland, James Scott McClellan, (unknown), Weily Soong, (unknown), Michael Sanders, (unknown), (unknown), (unknown), Sheri M. Routt, Leo Pezzementi	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact